Research Article| Volume 16, ISSUE 1, P104-111, January 2022

Download started.


Lower levels of low-density lipoprotein cholesterol are associated with a lower prevalence of thin-cap fibroatheroma in statin-treated patients with coronary artery disease

Published:December 03, 2021DOI:


      • Lower LDL-C levels with statins were associated with a lower prevalence of TCFAs.
      • A correlation between LDL-C and TCFAs was observed in patients with lower HbA1c.
      • LDL-C levels <70 mg/dL was independently associated with the lack of TCFAs.



      Reducing low-density lipoprotein cholesterol (LDL-C) levels with statins slows the progression of atherosclerotic plaques and reduces cardiovascular events. The 2019 European Society of Cardiology/European Atherosclerosis Society guidelines recommend absolute LDL-C treatment targets of <100 mg/dL, <70 mg/dL and <55 mg/dL according to coexisting patient risk factors.


      To clarify the difference in the plaque characteristics of coronary lesions associated with these LDL-C levels in statin-treated patients.


      A total of 685 consecutive statin-treated patients with coronary artery disease (CAD) who underwent optical coherence tomography (OCT) imaging of culprit lesions were enrolled. The characteristics of culprit plaques evaluated by OCT were compared among the high LDL-C group (≥100 mg/dL, n=247), the moderate LDL-C group (70-100 mg/dL, n=289), the low LDL-C group (55-70 mg/dL, n=106) and the very low LDL-C group (<55 mg/dL, n=43).


      A significant trend toward a lower prevalence of thin-cap fibroatheroma (TCFA) associated with the LDL-C groups was observed (23.1, 18.3, 9.4 and 11.6%, respectively, in each group; p=0.002). A trend toward a lower prevalence of TCFAs associated with the LDL-C groups was also observed among patients with lower hemoglobin A1c (<6.2%; p=0.003). LDL-C <70 mg/dL (the low/very low group) was independently associated with the lack of TCFAs (odds ratio, 0.50; 95% confidence interval, 0.27-0.87, p=0.014).


      Lower LDL-C levels were associated with a lower prevalence of TCFAs in culprit plaques among statin-treated patients with CAD.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Clinical Lipidology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Scott S.
        Preventing coronary artery disease.
        ACSM's Heal Fit J. 2005; 9: 27-29
        • Scandinavian Simvastatin Survival Study Group
        Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).
        Lancet. 1994;
        • La Rosa JC
        • Conti CR
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        ACC Cardiosource Rev J. 2006; 15: 97-99
        • Cannon CP
        • Blazing MA
        • Giugliano RP
        • et al.
        Ezetimibe added to statin therapy after acute coronary syndromes.
        N Engl J Med. 2015; 372: 2387-2397
        • Sabatine MS
        • Giugliano RP
        • Keech AC
        • et al.
        Evolocumab and clinical outcomes in patients with cardiovascular disease.
        N Engl J Med. 2017; 376: 1713-1722
        • Schwartz GG
        • Steg PG
        • Szarek M
        • et al.
        Alirocumab and cardiovascular outcomes after acute coronary syndrome.
        N Engl J Med. 2018; 379: 2097-2107
        • Mach F
        • Baigent C
        • Catapano AL
        • et al.
        2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.
        Eur Heart J. 2020; 41: 111-188
        • Okazaki S
        • Yokoyama T
        • Miyauchi K
        • et al.
        Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH study.
        Circulation. 2004; 110: 1061-1068
        • Nicholls SJ
        • Libby P
        • Raichlen JS
        • et al.
        Effect of Very High-Intensity Statin Therapy.
        Change. 2006; 295: 1556-1565
        • Takarada S
        • Imanishi T
        • Kubo T
        • et al.
        Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: Assessment by optical coherence tomography study.
        Atherosclerosis. 2009; 202: 491-497
        • Komukai K
        • Kubo T
        • Kitabata H
        • et al.
        Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: The EASY-FIT study.
        J Am Coll Cardiol. 2014; 64: 2207-2217
        • Grundy SM
        • Stone NJ
        • Bailey AL
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 73: e285-e350
        • Besseling J
        • Kindt I
        • Hof M
        • Kastelein JJP
        • Hutten BA
        • Hovingh GK.
        Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: A study of a cohort of 14,000 mutation carriers.
        Atherosclerosis. 2014; 233: 219-223
        • Jang IK
        • Tearney GJ
        • MacNeill B
        • et al.
        In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography.
        Circulation. 2005; 111: 1551-1555
        • Tearney GJ
        • Regar E
        • Akasaka T
        • et al.
        Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: A report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation.
        J Am Coll Cardiol. 2012; 59: 1058-1072
        • Kitabata H
        • Tanaka A
        • Kubo T
        • et al.
        Relation of Microchannel Structure Identified by Optical Coherence Tomography to Plaque Vulnerability in Patients With Coronary Artery Disease.
        Am J Cardiol. 2010; 105: 1673-1678
        • Liu L
        • Gardecki JA
        • Nadkarni SK
        • et al.
        HHS Public Access. 2012; 17: 1010-1014
        • Di Vito L
        • Yoon JH
        • Kato K
        • et al.
        Comprehensive overview of definitions for optical coherence tomography-based plaque and stent analyses.
        Coron Artery Dis. 2014;
        • Matsumoto D
        • Shite J
        • Shinke T
        • et al.
        Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: Evaluated by optical coherence tomography.
        Eur Heart J. 2007; 28: 961-967
        • Borén J
        • John Chapman M
        • Krauss RM
        • et al.
        Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel.
        Eur Heart J. 2020; 41: 2313-2330
        • Baigent C
        • Blackwell L
        • Emberson J
        • et al.
        Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Catapano AL
        • Graham I
        • De Backer G
        • et al.
        2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.
        Eur Heart J. 2016; 37: 2999-3058l
        • Virmani R
        • Kolodgie FD
        • Burke AP
        • Farb A
        • Schwartz SM.
        Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1262-1275
        • Kataoka Y
        • Hammadah M
        • Puri R
        • et al.
        Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels.
        Atherosclerosis. 2015; 242: 490-495
        • Farkouh ME
        • Godoy LC
        • Brooks MM
        • et al.
        Influence of LDL-Cholesterol Lowering on Cardiovascular Outcomes in Patients With Diabetes Mellitus Undergoing Coronary Revascularization.
        J Am Coll Cardiol. 2020; 76: 2197-2207
        • Sud M
        • Han L
        • Koh M
        • et al.
        Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention.
        J Am Coll Cardiol. 2020; 76: 1440-1450
        • Teramoto T
        • Uno K
        • Miyoshi I
        • et al.
        Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan.
        Atherosclerosis. 2016; 251: 248-254